Prospective Study on Prescribing Pattern and Short-Term Outcomes of SGLT-2 Inhibitors in a Tertiary Care Hospital
Abstract
BACKGROUND:
Sodium glucose co-transporter (SGLT-2) inhibitors are new class of antidiabetic therapy and shown to reduce cardiovascular mortality and heart failure in patients with T2DM with previous CV events or established cardiovascular disease. The aim of the study was to determine the prescribing pattern and short-term outcomes of SGLT-2 inhibitors. The primary outcome was to study the effect of SGLT-2 inhibitor as an add-on to insulin.
METHODS:
The prospective observational study was conducted which included 315 patients receiving SGLT-2 inhibitors for the management of T2DM mellitus with eGFR ≥40ml/min/1.73m2. The study population was divided into two- SGLT-2 + insulin ±OHA and SGLT-2 + OHA, which were further sub-divided based on duration of diabetes i.e., patients with ≤5 years and >5 years of T2DM respectively. The study was followedup at 2 months and 4 months. At the time of entry, complete medical history and laboratory evaluation were obtained. Patients demographics were also considered and recorded. The change in HbA1C, FBS, RBS, body weight, BMI, and lipid profile were measured at 2 month and 4 months. The patients were interviewed to assess ADR (if any) and it was confirmed by Naranjo ADR Scale. The adherence of the patients toward the medication was assessed with Morisky patient medication adherence scale.
RESULT:
The study showed that empagliflozin + biguanides + insulin + DPP-4 was the most prescribed combination. The glucose lowering (HbA1c, FBS and RBS)…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.